Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.53 - $26.42
Previous CloseN/A
Volume457.00K
Average Volume (3M)141.48K
Market Cap
$120.38M
Enterprise Value$139.20M
Total Cash (Recent Filing)$45.38M
Total Debt (Recent Filing)$87.43M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 18, 2025EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.27
Shares Outstanding8,754,570
10 Day Avg. Volume117,624
30 Day Avg. Volume141,478
Financial Highlights & Ratios
PEG Ratio-189.72
Price to Book (P/B)187.37
Price to Sales (P/S)0.00
P/FCF Ratio-17.34
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$14.00Price Target Upside-8.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Efficacy DataSER-155 demonstrated initial signs of efficacy with a 77% relative risk reduction in bloodstream infections, as well as benefit on other measures vs. placebo.
Regulatory SupportSER-155 has breakthrough designation, which should speed discussion with FDA.
Strategic PartnershipsSeres is still engaging with partnership discussion, and recent progress on SER-155 should boost opportunities.
Bears Say
Financial NeedsMCRB requires additional capital to support the study and stated that partnership discussions are advancing.
Leadership ChangesLong-time CEO Eric Shaff would depart the company, with CLO Thomas DesRosier and CFO Marella Thorell appointed as co-CEOs.
Uncertainty In Study DesignUncertainty around SER-155 study design and partnership discussion led to a lower probability of success from 35% to 20% and an increased discount rate from 6% to 34%.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $6.53 and its highest was $26.42 in the past 12 months.
What is Seres Therapeutics’s market cap?
Seres Therapeutics’s market cap is $120.38M.
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 101 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Aug 06, 2025. The company reported -$2.27 earnings per share for the quarter, beating the consensus estimate of -$2.49 by $0.22.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Overvalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is 0.42.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 8,754,570 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -$2.27 in its last earnings report, beating expectations of -$2.49. Following the earnings report the stock price went down -3.501%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Currently, no hedge funds are holding shares in MCRB
Seres Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (-8.44% Downside)
$14.00 (-8.44% Downside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 235.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 7.8%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.12%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-55.30%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome therapeutics. The company operates in the healthcare sector and is dedicated to creating innovative treatments for diseases by harnessing the therapeutic potential of the human microbiome. Seres Therapeutics' core products include a pipeline of biologically-derived drugs aimed at treating diseases such as Clostridium difficile infection (CDI) and other conditions linked to dysbiosis of the gut microbiota.
MCRB Company Deck
MCRB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical developments, particularly with SER-155, and effective financial management. However, challenges remain in funding and the broader biotech environment, creating a balanced view between achievements and hurdles.View all MCRB earnings summariesMCRB Stock 12 Month Forecast
Average Price Target
$14.00
▼(-8.44% Downside)
Technical Analysis
Jasper Therapeutics
―
Elicio Therapeutics
―
Vor Biopharma
―
Instil Bio
―
Senti Biosciences
―
Ownership Overview
0.45% Insiders
11.15% Mutual Funds
13.81% Other Institutional Investors
70.80% Public Companies and
Individual Investors